The Technology
This breakthrough innovation helps doctors protect the hearts of women undergoing breast cancer treatment. Many breast cancer therapies, especially chemotherapy, can quietly damage heart muscle long before symptoms appear. This AI-powered echocardiography platform enables early detection of heart injury caused by chemotherapy, allowing doctors to adjust treatment in time to prevent irreversible heart failure and preserve both heart health and life expectancy.
Developed at the Technion with leading Israeli hospitals, the system combines ultrasound imaging and artificial intelligence to recognize subtle, hidden signs of cardiac stress specific to breast cancer patients. Its proprietary algorithm analyzes how different layers of the heart muscle move during each beat, identifying early functional changes that conventional measures often miss. Integrating imaging, and biomarkers, it detects early cardiotoxicity with over 85% accuracy and fits seamlessly into existing hospital ultrasound systems—bringing advanced AI-driven cardiac protection directly to oncology care.
Advantages
- Early, actionable diagnosis – identifies cardiac risk months before symptoms.
- Non-invasive and cost-effective – operates on standard echocardiography equipment.
- AI-driven precision – ensures consistent, objective interpretation across users and sites.
- Improved patient outcomes – enables timely intervention to prevent heart failure.
- Seamless integration – compatible with leading ultrasound systems used in hospitals.
Applications
- Breast cancer treatment monitoring – real-time cardiac assessment during chemotherapy.
- Cardio-oncology programs – personalized treatment planning for high-risk patients.
- Pharmaceutical research – objective evaluation of drug-induced heart effects.
- Medical imaging manufacturers – integration as an AI software module in ultrasound systems.
- Preventive cardiology – early screening tool for heart dysfunction in cancer survivors
Business Development Contacts